Optimizing the Size of Drug-Loaded Nanoparticles Using Design of Experiments: Solid Lipid Nanoparticles

Optimizing the Size of Drug-Loaded Nanoparticles Using Design of Experiments: Solid Lipid Nanoparticles

Paola Cervantes-Covarrubias, Ayla Vea-Barragan, Aracely Serrano-Medina, Eugenia Gabriela Carrillo-Cedillo, José Manuel Cornejo-Bravo
Copyright: © 2021 |Pages: 27
DOI: 10.4018/978-1-7998-8591-7.ch015
OnDemand:
(Individual Chapters)
Available
$37.50
Current Special Offers
No Current Special Offers
TOTAL SAVINGS: $37.50

Abstract

Nanoparticles formed from lipids are currently applied successfully to deliver drugs. The particle size of the nanoparticle system is an essential characteristic to enhance the entrance of the drugs inside tissues and cells. Using design of experiment is appealing to find the specific conditions to optimize particle size of drug-loaded nanoparticles. Authors of this chapter applied a fractional factorial design of half fraction 24-1 with levels between continue factors, finding statistically significant differences for two factors such as concentrations of drugs and type of solvent where the organic phase is dissolved. This design shows the optimization of a formulation of capsaicin in solid lipid nanoparticles. The chapter also includes information on methods to prepare solid lipid nanoparticles (SLN), the variables involved, and a selection of studies about optimization of SLN formulations.
Chapter Preview
Top

Background

Lipid-based carriers are particularly suited for topical application (Mahant, Rao, & Nanda, 2018). Liposomes are spherical vesicles composed of one or more phospholipid bilayers, representing the first generation of the novel lipid colloidal carriers after submicron emulsion-bases products were developed in 1960s (Joshi & Müller, 2009; Mehnert & Mäder, 2012). Liposomes offered encapsulation of hydrophobic and hydrophilic drugs but have many disadvantages, including short shelf life, poor stability, low encapsulation efficacy, and cell interactions (Czajkowska-Kośnik, Szekalska, & Winnicka, 2019).

In 1990s Müeller started exploring the potential of nanoparticles-based on solid lipids. This drug delivery system was developed as an alternative system for poorly water-soluble drugs. The lipid phase of an SLN is solid at body and room RT. These lipid carriers minimize problems connected with traditional drug formulations and have some advantages, such as ease of preparation, good biocompatibility, lower cytotoxicity, avoidance of organic solvents, and wide possibilities of applications (Czajkowska-Kośnik et al., 2019; Müller, Mder, & Gohla, 2000).

Complete Chapter List

Search this Book:
Reset